Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
Table 2
Comparison of patients eligible for DAPA-HF compared to ineligible patient according to exclusion criteria.
Characteristic
Patients eligible for DAPA-HF ()
Patients not eligible due to NT-proBNP below threshold ()
Patient not eligible due to ()
value
value
Age-yr
79 (±10.0)
70.9 (±12.3)
<0.001
84.0 (±8.0)
<.001
Female sex-no. (%)
119 (33.8)
52 (23.6
0.02
33 (39.3)
0.41
Body mass index-kg/m2
26.4 (±4.9)
28.7 (±5.0)
<0.001
27.3 (±4.9)
0.13
Heart rate- beats/min
75.6 (±17.3)
71.3 (±13.9)
0.002
76.7 (±15.3)
0.2
Systolic blood pressure-mmHg
124 (±18.2)
125 (±16.8)
0.2
128 (±19.5)
0.6
Left ventricle ejection fraction-%
32.4 (±6.8)
34.8 (±5.6)
<0.001
32.9 (±6.5)
0.59
Median NT-proBNP-Pg/ml (IQR)
1943 (1138-3562)
286 (164-476)
3409.5 (1785-7073.75)
eGFR-ml/min/1.73 m2
54.4 (±15.0)
65.5 (±17.8)
<0.001
21.5 (±5.9)
<0.001
Rate of eGFR <60 ml/min/1.73 m2-no./total no. (%)
239/352 (67.9)
75/203 (36.9)
<0.001
84/84 (100)
Hospitalization for heart failure-no. (%)
182 (51.7)
102 (47.8)
0.42
39 (58.2)
0.2
Atrial fibrillation-no. (%)
198 (56.3)
65 (32.0)
<0.001
46 (54.8)
0.9
Diabetes mellitus-No. (%)
74 (21.0)
58 (28.6)
0.06
35 (41.7)
<.001
Hypertension-no. (%)
222 (63.1)
137 (67.4)
0.34
69 (82.1)
.001
Ischemic etiology-no. (%)
163 (46.3)
106 (48.2)
0.52
41 (48.8)
0.77
Heart failure treatment
ACE-inhibitor or ARB-no. (%)
258 (73.3)
151 (74.4)
0.86
68 (81.0)
0.19
ARNI-no. (%)
63 (17.9)
45 (22.5)
0.27
4 (4.8)
0.005
Beta blocker-no. (%)
322 (91.5)
192 (94.6)
0.24
78 (92.9)
0.8
MRA-no. (%)
213 (60.6)
136 (67.0)
0.15
35 (41.7)
0.003
Loop diuretics-no. (%)
233 (66.2)
96 (47.3)
<.001
76 (90.5)
<.001
Digitalis-no. (%)
56 (15.9)
26 (12.8)
0.39
13 (15.5)
1
ICD-no. (%)
47 (13.4)
52 (25.6)
<.001
6 (7.1)
0.17
CRT-no. (%)
53 (15.1)
37 (18.2)
0.39
12 (14.3)
0.9
Number in parentheses is ±1 standard deviation; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor blocker and neprilysin inhibitor; MRA: mineral corticoid antagonist; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy. values are in relation to the eligible patients. BMI available for 333/352 patients. BMI available for 197/203 patients. BMI available for 82/84 patients.
